Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Jörg B. Engel"'
Autor:
Renzhi Cai, Daniela Hornung, Achim Rody, Yuanming Shen, Li Jin, Jörg B. Engel, Andrew V. Schally, Frank Köster, Gabriele Marschner, Norman L. Block, D. Finas
Publikováno v:
Reproductive Sciences. 24:1503-1511
Endometriosis is a benign gynecologic disorder causing dysmenorrhea, pelvic pain, and subfertility. Receptors for the growth hormone-releasing hormone (GHRH) were found in endometriotic tissues. Antagonists of GHRH have been used to inhibit the growt
Autor:
Arnd Honig, Jörg B. Engel, Jens C. Hahne, Andrea Lampis, Susanne R. Meyer, Domenico Zito, Nicola Valeri
Publikováno v:
Clinical Cancer Drugs. 4:47-58
Publikováno v:
Current Drug Targets. 17:488-494
Receptors for LHRH (luteinizing hormone-releasing hormone) are expressed in about 80% of human endometrial, ovarian and prostate cancers and are also found in more than 50% of breast cancers including triple negative breast cancers. In the human body
Publikováno v:
Journal of Endometriosis and Pelvic Pain Disorders. 7:19-26
Agonists of luteinizing hormone-releasing hormone (LHRH) induce a reversible hypoestrogenic state through the down-regulation of LHRH receptors and desensitization of the pituitary. Since endometrial implants are estrogen sensitive, LHRH agonists hav
Publikováno v:
Hysterectomy ISBN: 9783319224961
Intraabdominal adhesions are the most frequent complication of abdominal surgery and may represent one of the greatest unsolved problems in medicine today. They severely diminish quality of life of many patients who are affected by bowel obstruction,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0a82bbe5d5d69dd282f749085b7c37c
https://doi.org/10.1007/978-3-319-22497-8_26
https://doi.org/10.1007/978-3-319-22497-8_26
Autor:
Jörg B. Engel, Olaf Ortmann
Publikováno v:
Frauenheilkunde up2date. 7:363-373
Autor:
Johannes Dietl, Michaela Kapp, Jörg B. Engel, SE Segerer, Arnd Honig, Jens C. Hahne, Susanne R. Meyer
Publikováno v:
Archives of Gynecology and Obstetrics. 289:141-147
Triple negative breast cancers (TNBC) are associated with an adverse outcome, although these tumors are sensitive to chemotherapy. In part, this phenomenon could be caused by tumor immune escape. The current study investigates immunogenicity of TNBC
Publikováno v:
Gynecologic Cancers-Basic Sciences, Clinical and Therapeutic Perspectives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52596369862ef84a284a53ebc01ec432
http://www.intechopen.com/articles/show/title/analysing-molecular-mechanism-related-to-therapy-resistance-in-in-vitro-models-of-ovarian-cancer
http://www.intechopen.com/articles/show/title/analysing-molecular-mechanism-related-to-therapy-resistance-in-in-vitro-models-of-ovarian-cancer
Autor:
Arnd Honig, Antonia Djakovic, Susanne R. Meyer, Mathias Krockenberger, Jörg Wischhusen, Jens C. Hahne, Johannes Dietl, Sebastian Häusler, Jörg B. Engel, SE Segerer, Theresa Martens
Publikováno v:
Anti-Cancer Drugs. 23:426-436
Lobaplatin as a single agent and in combination with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is investigated in in-vitro models of p53-negative triple-negative breast cancers (TNBCs) and compared with a model of oestrogen rec
Autor:
Andrew V. Schally, Roberto Perez, Jörg B. Engel, Alberto J. Montero, Norman L. Block, Stefan Buchholz, Stephan Seitz, Olaf Ortmann
Publikováno v:
Hormone Molecular Biology and Clinical Investigation. 9:87-94
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is clinically negative for the expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2). Patients with TNBC have a w